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background: Advances in treatment of complex lesion subsets can be furthered by development of new devices for new indications. The 
Evaluation of the XIENCE Coronary Stent, Performance, and Technique in Chronic Total Occlusions (EXPERT CTO) trial was designed to evaluate three 
types of devices (guide wires, balloons, and stents), each with their own primary endpoint, for the recanalization of CTO lesions.
Methods: EXPERT CTO is a prospective, single-arm trial examining the device-related outcomes in percutaneous CTO revascularization. The stent 
cohort tested the XIENCE V, XIENCE nano, and XIENCE PRIME Long Lesion stents in accessing and/or crossing CTO lesions, with a planned enrollment 
of approximately 250 subjects. The stent-related primary endpoint was major adverse cardiac events (MACE), defined as a composite of death, ARC-
defined myocardial infarction (MI), or clinically-driven target lesion revascularization (TLR) at 1 year post-procedure and was compared against a 
pre-specified performance goal derived from prior CTO studies. Secondary endpoints including device success and adverse clinical events were also 
evaluated for the stent cohort in the EXPERT CTO trial. Data are fully monitored and all endpoint events adjudicated by an independent committee.
results: A total of 222 subjects were successfully treated in the EXPERT CTO stent cohort. The trial has completed enrollment, and 1-year follow-up 
for all patients will be completed in January 2014. The principal objective, the primary stent-related endpoint along with 1-year secondary endpoints, 
will be available at the time of presentation.
conclusions: The EXPERT CTO trial has been performed to evaluate the safety and effectiveness of XIENCE stents to treat chronic total occlusions. 
The outcomes of the trial will provide important insights into the performance of the XIENCE family of stents in the treatment of these complex 
lesions. 
